Arvinas vs Moolec Science SA
Moolec Science SA is the larger business, with $334m of revenue in fiscal 2025 against $263m for Arvinas (1.3 times as much). Arvinas grew faster (-0.3% against -28.5%). Arvinas kept more of each dollar of sales as profit: a net margin of -30.8% against -33.4%.
| Latest fiscal year | ArvinasARVN, 2025 | Moolec Science SAMLEC, 2025 |
|---|---|---|
| Revenue | $263m | $334m |
| Revenue growth | -0.3% | -28.5% |
| Net income | −$80.8m | −$111m |
| Operating margin | -45.1% | -31.2% |
| Net margin | -30.8% | -33.4% |
| Return on equity | -16.2% | — |
| Free cash flow | −$276m | −$2.0m |
| Cash | $143m | $767,919 |
| Total debt | $600,000 | $1.3m |
| Debt to equity | 0.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $91.9m | — |
| Employees | 246 | — |
| Market value | $462m | $9.3m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 1 buys, 23 sales | 0 buys, 0 sales |